NEOTHETICS, INC. (NASDAQ:NEOT) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 20, 2017, Neothetics, Inc. (the Company), held its Annual
Meeting of Stockholders (the Annual Meeting). As of April 24,
2017, the record date of the Annual Meeting, there were
13,831,747 outstanding shares of the Companys common stock. At
the Annual Meeting, a quorum of 10,776,643 shares of the Companys
common stock were represented in person or by proxy. The Companys
stockholders elected a Class III director and approved the
ratification of the independent registered public accounting firm
as detailed below. Each of the voting matters (the Proposals) are
described in detail in the Companys definitive proxy statement
for the Annual Meeting that was filed with the Securities and
Exchange Commission on April 28, 2017. The final votes on the
Proposals presented at the Annual Meeting are as follows:

Proposal 1

Kim P. Kamdar, Ph.D. was elected as a Class III director to hold
office until the 2020 Annual Meeting of Stockholders and until
her successor is elected and has qualified, or, if sooner, until
the directors death, resignation or removal, by the following
vote:

The following individuals are continuing directors with terms
expiring upon the 2018 Annual Meeting of Stockholders: Jeffrey M.
Nugent and Maxim Gorbachev.

The following individual is a continuing director with a term
expiring upon the 2019 Annual Meeting of Stockholders: Martha J.
Demski.

Proposal 2

The stockholders ratified the appointment of Ernst Young LLP as
the Companys independent registered public accounting firm for
the fiscal year ending December 31, 2017 by the following vote:

No other items were presented for stockholder approval at the
Annual Meeting.

About NEOTHETICS, INC. (NASDAQ:NEOT)

Neothetics, Inc. is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. It has completed Phase II development of LIPO-202. LIPO-202 is administered in a subcutaneous injection procedure that activates a natural metabolic process to shrink fat cells, without killing them, resulting in localized fat reduction, measurable results within four weeks and minimal risk with no downtime. The Company is developing a product candidate, LIPO-102, an injectable form of a combination of salmeterol xinafoate and fluticasone propionate. LIPO-102 is indicated for the treatment of the orphan indication of symptomatic exophthalmos, or protrusion of the eye from the orbit, associated with thyroid-related eye disease caused by the expansion of fat and muscle behind the eye.